Drug development, clinical trials, and industry dynamics—what changes timelines, risk, and competitive positioning.
Denali Therapeutics reported $3.6 million in first-quarter-on-market revenue for Avlayah, ahead of analyst expectations after the Hunter syndrome drug was approved on March 25 and launched in April. The company also raised third quarter revenue guidance to $10 million to $12 million.
Denali Therapeutics reported $3.6 million in first-quarter-on-market revenue for Avlayah, ahead of analyst expectations after the Hunter syndrome drug was approved on March 25 and launched in April. The company also raised third quarter revenue guidance to $10 million to $12 million.
READ MORE
Replimune is shifting from a prolonged regulatory fight to a measured commercial launch after the FDA approved Tudriqev for advanced melanoma. The company is betting that broad labeling and physician demand can support uptake in a market with limited options after anti-PD-1 treatment failure.
Boston’s reign as the epicenter of the biotech world is under scrutiny as industry dynamics, cost pressures, and standout news—including FDA approvals and advances in Alzheimer's research—raise questions about emerging centers of innovation.
BioVie faces a dramatic market setback after its Parkinson’s disease study results appear ambiguous, with the company highlighting an alternative trial endpoint not previously accepted by the FDA.
Sanofi announces the pause of a key Phase 2 lung study as its new CEO embarks on a rigorous review of the pharmaceutical giant’s pipeline amid a strategic push for long-term value creation.
Novo Nordisk's new CEO, Maziar Mike Doustdar, addresses pipeline setbacks and underlines innovation as a strategic necessity for the Danish pharmaceutical giant.
With pharma deal activity intensifying, analysts have identified several biotech firms as potential near-term M&A candidates, with Johnson & Johnson’s next move signaling a new era for sector consolidation.
Lisata Therapeutics has announced the termination of 72% of its workforce in the wake of a failed merger with Kuva Labs, escalating to a legal battle over an alleged breach of agreement.
As competitors escalate their acquisitions, Pfizer CEO Albert Bourla maintains confidence in a disciplined $7B bolt-on M&A approach, defending it on an earnings call and signaling patience even as rivals make aggressive moves.
Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to a merger of equals, creating a new major player in the CNS pharmaceutical landscape. The combined company will boast a portfolio of 11 commercialized products in critical mental health and neurological indications.
Rumors of an AstraZeneca and Bristol Myers Squibb merger are stirring speculation about the biggest pharma deal the industry has ever seen, with sweeping implications for competitive dynamics, strategy, and patient care on a global scale.
